Hepatitis Forums

Fatty Liver Disease Main Forums => Nonalcoholic Steatohepatitis (NASH) => Topic started by: Hep Editors on July 31, 2019, 11:12:17 am

Title: Experimental NASH Drug Fails in Late-Stage Study
Post by: Hep Editors on July 31, 2019, 11:12:17 am

Selonsertib, one of Gilead Sciences’ investigational therapies for non-alcoholic steatohepatitis (NASH), failed to outperform a placebo when used as a stand-alone treatment in a Phase III clinical trial, according to a statement from the company.

Selonsertib joins a growing list of drug candidates for fatty liver disease that do not work well alone; however, some may still have potential as components of combination therapy.

For more...
https://www.hepmag.com/article/experimental-nash-drug-fails-latestage-study